Cyclosporines classification mechanism of action dosage usage uses in Orthopedics side effects preventions everything related to this with appropriate illustrative images and flowcharts

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Searching Images

cyclosporine calcineurin inhibitor mechanism of action T cell activation NFAT

Loading Image

Reading File

Searching PubMed

cyclosporine orthopedics bone joint immunosuppression

Finding Sources

Searching Images

cyclosporine drug interactions CYP3A4 side effects nephrotoxicity hirsutism gingival

Loading Image

Searching the Web

cyclosporine uses orthopedics rheumatoid arthritis psoriatic arthritis reactive arthritis 2024 2025

Searching PubMed

cyclosporine rheumatoid arthritis methotrexate combination

This covers everything requested. Here's a quick orientation to the sections:

Section	Content
1. Classification	Chemical origin, drug class, position in immunosuppressant hierarchy
2. Mechanism of Action	Detailed step-by-step intracellular pathway with diagram
3. Visual flowchart	Bailey & Love's T-cell activation diagram showing CsA's exact site of action
4. Pharmacokinetics	Formulations, bioavailability, metabolism, excretion
5. Dosage	Indication-specific doses, monitoring targets
6. Uses — including Orthopedics	Full table including RA, psoriatic arthritis, perioperative management, GVHD, heterotopic ossification
7. Side Effects	Flowchart + clinical photo of gingival hyperplasia
8. Drug Interactions	CYP3A4 inducers/inhibitors, additive toxicities
9. Monitoring	Parameters, frequency, targets
10–11. Contraindications & Prevention	What to avoid, how to manage side effects
12. Comparison Table	CsA vs other immunosuppressants
13. Orthopedic Flowchart	Decision tree for CsA use in inflammatory joint disease

Cyclosporines classification mechanism of action dosage usage uses in Orthopedics side effects preventions everything related to this with appropriate illustrative images and flowcharts

Reading File

Finding Sources

Searching Images

cyclosporine calcineurin inhibitor mechanism T cell NFAT IL-2 cyclophilin pathway diagram

Searching Images

immunosuppressant drugs classification calcineurin mTOR antiproliferative site of action T cell

Reading File

Loading Image

Searching Images

cyclosporine gingival hyperplasia nephrotoxicity clinical photo side effect

Reading File

Loading Image

Searching Images

cyclosporine drug interactions CYP3A4 pharmacokinetics table

Finding Sources

Reading File

Finding Sources

Searching Images

rheumatoid arthritis joint destruction treatment DMARD flowchart algorithm

Loading Image

Searching PubMed

cyclosporine rheumatoid arthritis psoriatic arthritis efficacy

Searching the Web

cyclosporine orthopedics uses perioperative management transplant patients 2024

I now have comprehensive, authoritative data from multiple textbooks plus clinical images. Here is the complete, definitive reference:

🔬 CYCLOSPORINE (Cyclosporin A / CsA) — Complete Clinical Reference

SECTION 1 — CLASSIFICATION

Origin

Cyclosporine is a lipophilic cyclic polypeptide of 11 amino acids produced by the soil fungus Beauveria nivea (originally isolated as Tolypocladium inflatum). — Goodman & Gilman's

Pharmacological Classification

IMMUNOSUPPRESSANT DRUGS
│
├── 1. CALCINEURIN INHIBITORS (CNIs) ◄─── CYCLOSPORINE is here
│      ├── Cyclosporine (binds CYCLOPHILIN)
│      └── Tacrolimus   (binds FKBP-12)
│
├── 2. mTOR INHIBITORS
│      ├── Sirolimus (Rapamycin)
│      └── Everolimus
│
├── 3. COSTIMULATION BLOCKERS
│      └── Belatacept
│
├── 4. ANTIPROLIFERATIVES / ANTIMETABOLITES
│      ├── Mycophenolate mofetil (MMF)
│      └── Azathioprine
│
└── 5. CORTICOSTEROIDS
       └── Prednisolone, Methylprednisolone

— Lippincott Illustrated Reviews: Pharmacology, 7th ed.

SECTION 2 — MECHANISM OF ACTION

Visual Diagram (Fitzpatrick's Dermatology, Fig. 192-2):

Key mechanisms of calcineurin inhibitors: Cyclosporine binds cyclophilin, forming a complex that inhibits calcineurin and blocks NFAT dephosphorylation, preventing nuclear translocation and cytokine transcription (IL-2, IL-3, IL-4, TNF-α, IFN-γ, GM-CSF)

Figure 192-2 from Fitzpatrick's Dermatology: Cyclosporine binds cyclophilin → CsA–Cyclophilin complex binds calcineurin → blocks NFAT dephosphorylation → NFAT cannot translocate to nucleus → no cytokine gene transcription (IL-2, IL-3, IL-4, TNF-α, IFN-γ, GM-CSF)

Step-by-Step Molecular Cascade

NORMAL T-CELL ACTIVATION:
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
APC presents peptide (in MHC groove) to T-cell receptor
              ↓
    TCR + CD3 complex activation
              ↓
    Transmembrane signalling → ↑↑ intracellular Ca²⁺
              ↓
    Ca²⁺ binds CALMODULIN
              ↓
    Ca²⁺–Calmodulin activates CALCINEURIN
    (serine/threonine phosphatase: CnA catalytic + CnB regulatory subunits)
              ↓
    Calcineurin DEPHOSPHORYLATES cytoplasmic NFAT (NFATc)
              ↓
    NFATc translocates to NUCLEUS
              ↓
    NFATc + NFATn complex → binds cytokine gene promoters
              ↓
    TRANSCRIPTION: IL-2, IL-3, IL-4, TNF-α, IFN-γ, GM-CSF
              ↓
    T-cell ACTIVATION → PROLIFERATION → IMMUNE RESPONSE

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
HOW CYCLOSPORINE BLOCKS THIS:
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
CsA (lipophilic) → freely diffuses into T-cell cytoplasm
              ↓
    Binds CYCLOPHILIN (immunophilin receptor, high affinity)
              ↓
    CsA–Cyclophilin complex → BINDS CALCINEURIN
              ↓
    CALCINEURIN IS INHIBITED (phosphatase activity blocked)
              ↓
    NFATc remains PHOSPHORYLATED → CANNOT enter nucleus
              ↓
    NO cytokine gene transcription
              ↓
    NO IL-2 production → T-cell NOT activated
              ↓
    IMMUNOSUPPRESSION achieved

"CsA inhibits T-cell activation mediated by antigens by blocking the downstream signalling cascade of the T-cell receptor, but it does not inhibit the early phases of T-lymphocyte signal transduction." — Fitzpatrick's Dermatology, p. 3550

Additional Immune Effects

Effect	Details
Cyclophilin–apoptosis	Cyclophilin also mediates apoptosis and degranulation of cytotoxic T-lymphocytes — CsA inhibits this
TGF-β upregulation	CsA increases TGF-β, which further inhibits IL-2–stimulated T-cell proliferation
Humoral immunity	Partially suppressed (B-cell dependent on T-helper cells)
Antiapoptotic proteins	Blunts expression in lymphocytes

SECTION 3 — SITE OF ACTION AMONG IMMUNOSUPPRESSANTS

Bailey & Love's Surgery Fig. 88.10: Site of action of immunosuppressive agents on T cell activation — Calcineurin blockers (Ciclosporin, Tacrolimus) block the Early activation → Late activation transition; mTOR inhibitors block Late activation → Proliferation; Antiproliferatives block Proliferation

Bailey & Love's Short Practice of Surgery, 28th ed., Fig. 88.10 — Cyclosporine (calcineurin blocker) acts at the Early → Late T-cell activation transition, upstream of mTOR inhibitors and antiproliferatives.

SECTION 4 — FORMULATIONS & PHARMACOKINETICS (ADME)

Formulations

Product	Description	Note
SANDIMMUNE	Original soft gelatin capsule + oral solution	Erratic bioavailability (20–50%); AVOID switching
NEORAL	Modified microemulsion — most widely used	More uniform, slightly higher bioavailability; 25 mg & 100 mg capsules; 100 mg/mL solution
GENGRAF	Second modified formulation	Also NOT interchangeable with Sandimmune
IV formulation	Ethanol + polyoxyethylated castor oil vehicle; dilute in NS or D5W before injection	Discontinue IV → switch to oral ASAP; more adverse effects with IV route

⚠️ Critical safety point: SANDIMMUNE and NEORAL are NOT bioequivalent and cannot be substituted without close monitoring. Inadvertent substitution can cause graft loss or toxicity. — Goodman & Gilman's, p. 793

Pharmacokinetics Summary

PK Parameter	Detail
Absorption	Oral: incomplete, highly variable; food delays and reduces absorption (AUC ↓13%, Cmax ↓33% with high-fat meal)
Peak plasma level (Neoral)	1.5–4 hours post-dose
C2 level	Level at 2 h post-dose — better AUC correlate than trough C0 level
Volume of Distribution	3–5 L/kg (IV) in transplant recipients; 13 L/kg (Fitzpatrick's) — extensive extravascular distribution
Blood binding	Binds to lymphocytes, granulocytes, erythrocytes + plasma lipoproteins; whole blood levels preferred for monitoring
Half-life (t½)	5–18 hours (biphasic elimination); ~6–12 h in healthy subjects
Metabolism	Hepatic CYP3A4 primarily; also GI tract/kidneys; >30 metabolites (partially active)
Excretion	>90% biliary/fecal; only ~6% urinary; renal failure does not substantially alter clearance
Special populations	Hepatic dysfunction → dose reduction required; dialysis/renal failure → NO adjustment needed

SECTION 5 — DOSAGE

Indication	Standard Dose	Notes
Renal transplant	3–5 mg/kg/day PO ÷ 2 doses	Delay initiation until threshold renal function reached; guided by trough levels
Liver / Heart transplant	Protocol-dependent; typically 2–5 mg/kg/day	Combined with steroids ± MMF or azathioprine
Rheumatoid arthritis	2.5–4 mg/kg/day PO ÷ 2 doses	Severe RA unresponsive to MTX; can combine with MTX with close monitoring
Psoriasis (severe plaque)	2.5–5 mg/kg/day; optimal control up to 4–5 mg/kg/day	Short courses; avoid continuous use >1 year
Psoriatic arthritis	2.5–4 mg/kg/day	GRAPPA-recommended DMARD
Nephrotic syndrome	3–5 mg/kg/day	Minimal change disease, FSGS
Pediatric	Weight-based; adjusted to trough; monthly BP monitoring	JDM, MAS, JIA
IV (when oral not possible)	~⅓ of oral dose	Switch to oral as soon as feasible

Therapeutic Drug Monitoring Targets

Timeframe	Trough (C0) Target
0–3 months post-transplant	250–300 ng/mL
3–6 months	200–300 ng/mL
6–12 months	150–250 ng/mL
>12 months	100–150 ng/mL

C2 levels (2 h post-dose): 1000–1700 ng/mL in early post-transplant period (better AUC correlation)

SECTION 6 — THERAPEUTIC USES

6A — Transplantation

Kidney, liver, heart transplant: cornerstone CNI immunosuppression in combination regimens
Bone marrow / stem cell transplant: GVHD prophylaxis (combined with methotrexate — standard regimen)
Initial dose delayed in renal transplant until threshold renal function attained

6B — Rheumatologic / Musculoskeletal Conditions

Rheumatoid Arthritis — the Inflammation Cascade CsA Targets:

Harrison's diagram of RA immunopathogenesis: APC activates T cells → TH1 and TH17 → cytokines (IFN-γ, TNF-α, IL-17) → macrophages and synovial fibroblasts → MMP, RANK-L, bone destruction; cyclosporine blocks early T-cell activation in this cascade

Harrison's Principles of Internal Medicine 22E: RA immunopathogenesis — Cyclosporine interrupts the T-cell activation cascade at the very top of this diagram, preventing downstream cytokine production, synovial inflammation, and joint destruction

Condition	Role of Cyclosporine
Rheumatoid Arthritis	Used in severe RA unresponsive to methotrexate; can combine CsA + MTX (both levels monitored closely) — FDA-approved
Psoriatic Arthritis	GRAPPA strongly recommends CsA as a DMARD; controls skin + joint disease
Psoriasis (severe plaque)	Adult immunocompetent patients with severe, disabling disease where other systemic therapies contraindicated or failed
Behçet's disease	Especially for ocular and joint manifestations
Endogenous uveitis	Well-established
Atopic dermatitis	Established evidence
SLE (lupus)	ACR-recognized; especially renal and cutaneous involvement
Juvenile dermatomyositis (JDM)	Most common pediatric rheumatology use
Macrophage Activation Syndrome (MAS)	Associated with systemic JIA — rescue therapy
Inflammatory bowel disease	Rescue therapy for severe refractory Crohn's/UC
Nephrotic syndrome	Steroid-dependent / frequently relapsing minimal change disease, FSGS
Dry eye (xerophthalmia)	FDA-approved ophthalmic formulation (Restasis 0.05%)

6C — 🦴 Uses Specific to Orthopedics

Orthopedic Context	Role & Significance
Rheumatoid Arthritis (erosive joint disease)	Reduces synovial T-cell–driven inflammation; slows joint space narrowing in severe, MTX-refractory RA; used as DMARD before biologics
Psoriatic Arthritis with joint involvement	Controls both skin and joint disease; reduces enthesitis, dactylitis, and erosive damage; combined DMARD option
Reactive / inflammatory arthritis	Adjunct immunosuppression in refractory cases
Gout (secondary hyperuricemia)	CsA itself causes hyperuricemia → gout flares; orthopedic surgeons must recognize CsA as a cause of acute gout in transplant patients
Perioperative management of transplant recipients undergoing orthopedic surgery	CsA must be continued perioperatively (transplant patients); blood levels monitored daily; adjust for fluid dilution, drug interactions, and NPO status
GVHD (bone marrow transplant)	Prevents GVHD affecting musculoskeletal tissues (myopathy, fasciitis, arthropathy)
Macrophage Activation Syndrome (systemic JIA)	Rescue therapy affecting joints, bone marrow
Heterotopic ossification (emerging evidence)	NFAT pathway modulation by CNIs may affect ectopic bone formation; experimental data only — not standard of care

Perioperative Protocol for CsA (Orthopedic Surgery):

TRANSPLANT PATIENT ON CYCLOSPORINE → ORTHOPEDIC SURGERY
                    │
    ┌───────────────┼───────────────┐
    │               │               │
 CONTINUE        MONITOR         AVOID
CsA throughout  blood levels    NSAIDs
 perioperative    daily         (additive
  period       perioperatively nephrotoxicity)
    │               │               │
 If NPO →      Adjust dose for    Use
  IV CsA        fluid dilution   paracetamol/
  (~1/3 oral)  and drug          opioids
               interactions    post-op

"Patients with organ transplants should be continued on immunosuppressant medications unless directed otherwise by transplant physician." — Froedtert Hospital Perioperative Medication Guidelines

"Clinically significant reductions of cyclosporine blood levels can be caused by dilution with massive fluid infusion perioperatively and cardiopulmonary bypass." — IARS Anesthesia & Analgesia

SECTION 7 — SIDE EFFECTS

Master Adverse Effects Flowchart

CYCLOSPORINE ADVERSE EFFECTS
              │
    ┌─────────┼──────────────────────┐
    │         │                      │
RENAL    CARDIOVASCULAR          METABOLIC
    │         │                      │
Nephrotoxicity  Hypertension     ┌───┴────────────────────┐
(majority of    (~50% renal tx;  │ Hyperlipidemia (↑LDL)  │
 patients)      ~100% cardiac)   │ Hyperkalemia            │
    │                            │ Hyperuricemia → GOUT    │
 Acute:                          │ Hyperglycemia / DM      │
 renal vasoconstriction          │ Hypomagnesemia          │
 (reversible with                └────────────────────────┘
  dose reduction)
 Chronic:
 interstitial fibrosis
              │
    ┌─────────┼────────────────────────┐
    │         │                        │
COSMETIC  NEUROLOGICAL           ONCOLOGICAL
    │         │                        │
Hirsutism  Tremor (common)      ↑ Lymphoma risk
Gingival   Headache             Post-transplant
hyperplasia Paresthesias         lymphoproliferative
            Mental confusion     disorder (PTLD)
            Hallucinations       Skin malignancy
            Seizures (rare)      (SCC > BCC)
            PRES
              │
    ┌─────────┼─────────────┐
    │         │             │
INFECTIONS  GI           OTHER
    │         │             │
Opportunistic  Nausea     Pancreatitis
infections     Vomiting   Hepatotoxicity
(fungal,       Diarrhea   Dyspnea
bacterial,
viral — CMV)

Gingival Hyperplasia — Clinical Photographs

Cyclosporine-induced gingival overgrowth: severe lobulated, nodular fibrous tissue covering tooth crowns in transplant patient on CsA + calcium channel blocker; C: gingivectomy; E: resolution after switching to tacrolimus

Clinical photo series: A/B — severe cyclosporine-induced gingival overgrowth (lobulated, nodular); C — scalpel gingivectomy; D — dental plaque at margins; E — resolution after switching to tacrolimus

Cyclosporine-induced gingival hyperplasia: erythematous, edematous, bulbous interdental papillae covering tooth crowns with visible plaque accumulation in immunosuppressed transplant patient

Cyclosporine-induced gingival hyperplasia: note bulbous, erythematous gingival overgrowth covering clinical crowns — a hallmark cosmetic side effect of CNI therapy

Comparison: Cyclosporine vs. Tacrolimus Side Effects

Side Effect	Cyclosporine	Tacrolimus
Nephrotoxicity	✅ Yes (major)	✅ Yes (major)
Hypertension	✅ ~50% renal, ~100% cardiac	✅ Yes
Hirsutism	✅ More common	✗ Less; hair loss instead
Gingival hyperplasia	✅ Yes	✗ No
Hyperlipidemia (LDL ↑)	✅ More	Less
Hyperglycemia / DM	✅ (less than tacrolimus)	✅ More diabetogenic
Neurotoxicity	✅ Tremor, seizures	✅ More tremor, headache
Alopecia	✗ No	✅ Yes
Diarrhea	Less	More

SECTION 8 — DRUG INTERACTIONS

From Fitzpatrick's Dermatology (comprehensive table):

Interaction Type	Drug Class	Examples
↑ CsA levels (CYP3A4 inhibitors — ↑ toxicity risk)	Ca²⁺ channel blockers	Diltiazem, nicardipine, verapamil
	Antibiotics	Erythromycin, clarithromycin, azithromycin, quinupristin
	Antifungals	Fluconazole, itraconazole, ketoconazole, voriconazole
	Antivirals (HIV)	Ritonavir, indinavir, saquinavir, nelfinavir
	Glucocorticoids	Methylprednisolone
	Other	Allopurinol, amiodarone, bromocriptine, colchicine, danazol, metoclopramide, oral contraceptives
	Food	GRAPEFRUIT JUICE ⚠️ (CYP3A4 + P-gp inhibition)
↓ CsA levels (CYP3A4 inducers — ↓ efficacy)	Antibiotics	Rifampin, nafcillin
	Anticonvulsants	Carbamazepine, phenobarbital, phenytoin, oxcarbazepine
	Other	St. John's wort, bosentan, orlistat, octreotide, terbinafine
Additive TOXICITY	NSAIDs	Diclofenac, naproxen, sulindac, colchicine ⚠️ Nephrotoxicity
	Antibiotics	Ciprofloxacin, gentamicin, vancomycin, TMP-SMX
	Antifungals	Amphotericin B
	Immunosuppressants	Tacrolimus (synergistic nephrotoxicity — avoid)
	Antimetabolites	Methotrexate (↑ MTX levels), fibrates
CsA as inhibitor (CYP3A4 + P-gp)	CsA ↑ levels of:	Statins (↑ myopathy risk), prednisolone, digoxin, MTX

⚠️ Orthopedic Alert — NSAIDs + Cyclosporine: Additive nephrotoxicity. Commonly used post-op analgesics (diclofenac, naproxen, ketorolac) must be avoided or used with extreme caution in patients on cyclosporine. — Goodman & Gilman's, p. 794

SECTION 9 — MONITORING

Monitoring Protocol Flowchart

INITIATE CYCLOSPORINE
         │
BASELINE ASSESSMENTS
─────────────────────────────────────────────
 • Blood pressure (both arms)
 • Serum creatinine + eGFR
 • Full blood count (CBC)
 • Liver function tests
 • Fasting lipid panel
 • Uric acid
 • Blood glucose / HbA1c
 • Urinalysis (proteinuria)
 • CsA baseline levels (trough C0 or C2)
 • Dermatologic exam (skin cancer baseline)
         │
FIRST 3 MONTHS (most intensive)
─────────────────────────────────────────────
 • BP: at each visit
 • Creatinine: every 2 weeks
 • CsA trough (C0): weekly → every 2 weeks
 • C2 if used: exactly 2 h after dose
 • CBC + LFTs: monthly
         │
MONTHS 3–12 (stable phase)
─────────────────────────────────────────────
 • BP + Creatinine: monthly
 • CsA trough: monthly
 • Lipids + uric acid: every 3–6 months
 • Annual skin surveillance (SCC risk)
         │
TARGETS / ACTION THRESHOLDS
─────────────────────────────────────────────
 • Creatinine rise >30% from baseline
   → REDUCE DOSE or STOP
 • BP >130/80 → Antihypertensive (amlodipine
   preferred; avoid diltiazem/verapamil)
 • eGFR declining trend → Consider switch
   to tacrolimus or non-CNI

SECTION 10 — CONTRAINDICATIONS

Contraindication	Rationale
Uncontrolled hypertension	CsA worsens; increased stroke/renal risk
Significant renal impairment at baseline	Additive nephrotoxicity; may cause irreversible damage
Active uncontrolled infection	Immunosuppression will exacerbate
Current malignancy (especially lymphoma/skin)	CsA promotes tumor growth
Concomitant tacrolimus	Synergistic nephrotoxicity
Concomitant sirolimus (simultaneous)	Must time-separate (cyclosporine worsens sirolimus-induced hyperlipidemia; sirolimus worsens CsA nephrotoxicity)
Pregnancy	Teratogenic; discuss risk/benefit; ACR advises avoid
Breastfeeding	Excreted in breast milk
Hypersensitivity to polyoxyethylated castor oil	(IV formulation only)

SECTION 11 — PREVENTION & MANAGEMENT OF SIDE EFFECTS

Side Effect	Prevention	Management
Nephrotoxicity	Lowest effective dose; avoid NSAIDs, aminoglycosides, amphotericin; baseline renal assessment	Dose reduction (reversible); if graft dysfunction: biopsy to differentiate rejection vs. toxicity; switch to tacrolimus if persistent
Hypertension	Avoid high-sodium diet; monitor BP at every visit	Amlodipine (preferred CCB — no CYP3A4 interaction); ACE inhibitors; avoid diltiazem/verapamil
Gingival hyperplasia	Strict oral hygiene; regular dental review	Gingivoplasty/gingivectomy if severe; switch to tacrolimus (reverses overgrowth)
Hirsutism	Counsel patient pre-treatment	Cosmetic management; switch to tacrolimus if socially unacceptable
Hyperlipidemia	Low-fat diet; monitor lipids 3–6 monthly	Statins (pravastatin preferred — least CYP3A4 interaction); avoid lovastatin/simvastatin (high myopathy risk with CsA)
Hyperuricemia / Gout	Avoid allopurinol (unless dose-adjusted — allopurinol ↑ CsA levels); low-purine diet	Colchicine (caution: CsA ↑ colchicine toxicity → use low dose); dose reduction
Hyperkalemia	Low-potassium diet; avoid K-sparing diuretics	Kayexalate; dose reduction
Infection risk	PCP prophylaxis (TMP-SMX); CMV prophylaxis post-transplant; antifungal prophylaxis	Treat aggressively; consider dose reduction
Malignancy	Sun protection (SPF 50+); annual skin surveillance; avoid prolonged high-dose use; avoid combination with UV therapy	Dermatology surveillance; switch immunosuppression class; consider mTOR inhibitors (sirolimus has antitumor properties)
Neurotoxicity (tremor, seizures)	Maintain therapeutic drug levels	Dose reduction; if seizures: avoid hyperventilation perioperatively; lower seizure threshold with CsA

SECTION 12 — MAINTENANCE IMMUNOSUPPRESSANT COMPARISON TABLE

(Lippincott Illustrated Reviews: Pharmacology)

Drug	Class	Key Indications	PK	Adverse Effects
Cyclosporine	CNI	SOT, psoriasis, RA, GVHD	CYP3A4; P-gp inhibitor	HTN, nephrotoxicity, hirsutism, gingival hyperplasia, HLD, neurotoxicity
Tacrolimus	CNI	SOT, GVHD	CYP3A4	HTN, nephrotoxicity, DM, alopecia, neurotoxicity
Sirolimus	mTOR inhibitor	SOT (renal, heart), GVHD	CYP3A4	Impaired wound healing ⚠️, HLD, proteinuria, myelosuppression
Everolimus	mTOR inhibitor	SOT, oncology	CYP3A4	Same as sirolimus; stomatitis
Mycophenolate	Antiproliferative	SOT, SLE	Glucuronidation	Myelosuppression, GI effects
Azathioprine	Antiproliferative	SOT, RA, lupus	Thiopurine pathway	Myelosuppression, hepatotoxicity, pancreatitis
Corticosteroids	Corticosteroid	Many	—	HTN, osteoporosis, DM, Cushing's
Belatacept	Costimulation blocker	SOT (renal)	t½ ~10 days	↑ PTLD risk, anemia

Orthopedic Note on Sirolimus: Unlike cyclosporine, sirolimus significantly impairs wound healing — this is a critical distinction when managing post-surgical patients.

SECTION 13 — CLINICAL DECISION FLOWCHART: Cyclosporine in Orthopedic / Rheumatologic Practice

PATIENT WITH INFLAMMATORY JOINT DISEASE
(RA / Psoriatic Arthritis / Reactive Arthritis)
                       │
                       ▼
       ┌───────────────────────────────┐
       │   STEP 1: FIRST-LINE DMARDs   │
       │ Methotrexate (MTX)            │
       │ Sulfasalazine                 │
       │ Hydroxychloroquine            │
       └───────────────┬───────────────┘
                       │
              Adequate response?
              YES ─────┴────── NO
               │                 │
          Continue            3–6 months
         & Monitor            inadequate
                                 │
                                 ▼
         ┌─────────────────────────────────────┐
         │  STEP 2: CONSIDER CYCLOSPORINE       │
         │  Indication:                         │
         │  • RA refractory to MTX              │
         │  • Severe psoriatic arthritis         │
         │  • Cannot use biologics              │
         │  Dose: 2.5–4 mg/kg/day PO ÷ 2       │
         └────────────────┬────────────────────┘
                          │
         Can add MTX to CsA? YES — monitor BOTH levels
                          │
            ┌─────────────▼────────────────────┐
            │   BASELINE ASSESSMENTS           │
            │ BP, Cr, eGFR, CBC, LFTs,         │
            │ Lipids, Uric acid, UA, CsA level  │
            └─────────────┬────────────────────┘
                          │
              Monitor q2 weeks × 3 months
              then monthly
                          │
               ┌──────────┴──────────┐
               │                     │
        Adequate response        Inadequate response
        & tolerable                or side effects
               │                     │
          Continue at           ┌────┴──────────────┐
          lowest effective      │                    │
           dose                Dose              Switch to:
                               adjust         • Tacrolimus
                                              • Biologic DMARD
                                                (TNF-i, IL-17-i)
                                              • JAK inhibitor

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
PERIOPERATIVE PATHWAY (Orthopedic Surgery)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Patient on CsA → ELECTIVE ORTHO SURGERY
         │
         ├─ TRANSPLANT patient → CONTINUE CsA throughout
         │                       (consult transplant team)
         │
         ├─ RA/PsA patient (non-severe SLE) → CONTINUE CsA
         │                                    (ACR guidelines)
         │
         ├─ NPO perioperatively → SWITCH to IV CsA (~1/3 oral dose)
         │
         ├─ AVOID NSAIDs postoperatively (additive nephrotoxicity)
         │   → Use paracetamol, opioids, COX-2 (with caution)
         │
         ├─ Monitor CsA blood levels DAILY perioperatively
         │
         └─ Check for drug interactions with anesthetic agents
            and antibiotics used

KEY CLINICAL PEARLS — Quick Reference

Situation	Key Point
NSAIDs + CsA	Additive nephrotoxicity — use paracetamol instead post-op
Formulation switch	SANDIMMUNE ≠ NEORAL — never switch without close monitoring
Grapefruit	Inhibits CYP3A4 → ↑ CsA levels → toxicity
Rifampin / Phenytoin	Dramatically ↓ CsA levels → rejection risk
Statin choice	Use pravastatin (least CYP3A4); avoid lovastatin/simvastatin
Gout flare on CsA	CsA causes hyperuricemia; recognize as CsA complication; low-dose colchicine
BP management	Amlodipine preferred; NOT diltiazem/verapamil (↑ CsA levels)
Wound healing	CsA does NOT impair wound healing (unlike sirolimus/everolimus)
Creatinine ↑ >30%	Reduce dose immediately; if persistent → biopsy or switch
Gingival hyperplasia	Switch to tacrolimus — resolves within months

References

Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed., Chapter 39
Fitzpatrick's Dermatology, 9th ed., Chapter 192 (Calcineurin Inhibitors)
Lippincott Illustrated Reviews: Pharmacology, 8th ed., Chapter 38
Harrison's Principles of Internal Medicine, 22nd ed. (2025)
Bailey & Love's Short Practice of Surgery, 28th ed., Chapters 88–89
Sabiston Textbook of Surgery, 21st ed.
National Kidney Foundation Primer on Kidney Diseases, 8th ed.
ACR 2017 Guideline — Perioperative Management of Antirheumatic Medications
ACR Patient Education — Cyclosporine (updated February 2025)
GRAPPA Guidelines for Psoriatic Arthritis

This is a shared conversation. Sign in to Orris to start your own chat.